• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    12/22/21 4:32:04 PM ET
    $ADXS
    $ANPC
    $BCDA
    $BRTX
    Major Pharmaceuticals
    Health Care
    Medical Specialities
    Health Care
    Get the next $ADXS alert in real time by email

    Gainers

    • BioCardia (NASDAQ:BCDA) shares rose 29.91% to $2.91 during Wednesday's after-market session. At the close, BioCardia's trading volume reached 793.9K shares. This is 471.05% of its average volume over the last 100 days. The company's market cap stands at $49.0 million.
    • AnPac Bio-Medical Science (NASDAQ:ANPC) shares moved upwards by 8.91% to $1.1. The market value of their outstanding shares is at $19.5 million.
    • BioSig Technologies (NASDAQ:BSGM) shares rose 5.19% to $2.43. The market value of their outstanding shares is at $85.8 million.
    • Quoin Pharmaceuticals (NASDAQ:QNRX) stock moved upwards by 4.71% to $2.0. The company's market cap stands at $16.6 million.
    • Evoke Pharma (NASDAQ:EVOK) shares increased by 4.45% to $0.64. The market value of their outstanding shares is at $20.7 million.
    • Genfit (NASDAQ:GNFT) shares rose 4.26% to $5.87. The company's market cap stands at $268.5 million.

    Losers

    • Advaxis (NASDAQ:ADXS) shares declined by 30.0% to $0.17 during Wednesday's after-market session. Advaxis's trading volume hit 3.9 million shares by close, accounting for 87.55% of its average volume over the last 100 days. The market value of their outstanding shares is at $24.4 million.
    • Ensysce Biosciences (NASDAQ:ENSC) stock fell 7.65% to $4.47. Trading volume for this security closed at 365.8K, accounting for 6.42% of its average full-day volume over the last 100 days. The company's market cap stands at $108.4 million.
    • Roivant Sciences (NASDAQ:ROIV) shares declined by 5.15% to $11.24. The market value of their outstanding shares is at $7.6 billion.
    • BiondVax Pharmaceuticals (NASDAQ:BVXV) shares decreased by 4.46% to $2.79. At the close, BiondVax Pharmaceuticals's trading volume reached 359.4K shares. This is 459.89% of its average volume over the last 100 days. The company's market cap stands at $39.9 million.
    • Midatech Pharma (NASDAQ:MTP) shares fell 4.1% to $1.17. The company's market cap stands at $14.8 million.
    • BioRestorative Therapies (NASDAQ:BRTX) shares fell 3.54% to $5.18. The market value of their outstanding shares is at $18.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADXS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADXS
    $ANPC
    $BCDA
    $BRTX

    CompanyDatePrice TargetRatingAnalyst
    Roivant Sciences Ltd.
    $ROIV
    3/20/2026$35.00Outperform
    Bernstein
    Roivant Sciences Ltd.
    $ROIV
    9/2/2025$16.00Buy
    Citigroup
    GENFIT S.A.
    $GNFT
    8/19/2025$9.00Buy
    H.C. Wainwright
    Roivant Sciences Ltd.
    $ROIV
    7/10/2025$19.00Buy
    Goldman
    Roivant Sciences Ltd.
    $ROIV
    2/15/2024$17.00Outperform
    Wolfe Research
    Roivant Sciences Ltd.
    $ROIV
    1/5/2024$20.00Overweight
    Piper Sandler
    Roivant Sciences Ltd.
    $ROIV
    12/12/2023$14.00Buy
    Deutsche Bank
    Roivant Sciences Ltd.
    $ROIV
    10/17/2023$17.00Buy
    Guggenheim
    More analyst ratings

    $ADXS
    $ANPC
    $BCDA
    $BRTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for GIMOTI

    Submission status for EVOKE PHARMA INC's drug GIMOTI (SUPPL-1) with active ingredient METOCLOPRAMIDE HYDROCHLORIDE has changed to 'Approval' on 01/14/2021. Application Category: NDA, Application Number: 209388, Application Classification: Labeling

    1/15/21 5:10:35 AM ET
    $EVOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXS
    $ANPC
    $BCDA
    $BRTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioCardia Files Request for Meeting With FDA to Discuss Accelerated Approval Pathway for CardiAMP® System in Ischemic Heart Failure

    SUNNYVALE, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported submission to United States Food and Drug Administration (FDA) of the CardiAMP HF clinical study data and on its plans to meet with the FDA to discuss the accelerated approval pathway for the CardiAMP® System for ischemic chronic heart failure with reduced ejection fraction (HFrEF). This meeting request is in line with previous guidance and BioCardia expects to have the meeting during this quarter. The meeting will be held under BioCardia's FDA Breakthrough Designation for

    4/2/26 10:11:34 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)

    Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved therapies exist for LPP, highlighting a critical unmet therapeutic needLPP marks the fourth indication in brepocitinib's expanding late-stage development programMultiple lines of evidence, including strong mechanistic rationale and clinically meaningful results in an investigator-initiated placebo-controlled study of brepocitinib in LPP, support rapid development of brepocitinib in this indicationA seamless Phase 2b/3 potentially registrational trial of brepocitinib in LPP enrolled its

    4/2/26 5:00:00 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

    Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved therapies exist for LPP, highlighting a critical unmet therapeutic needLPP marks the fourth indication in brepocitinib's expanding late-stage development programMultiple lines of evidence, including strong mechanistic rationale and clinically meaningful results in an investigator-initiated placebo-controlled study of brepocitinib in LPP, support rapid development of brepocitinib in this indicationA seamless Phase 2b/3 potentially registrational trial of brepocitinib in LPP enrolled its

    4/2/26 5:00:00 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXS
    $ANPC
    $BCDA
    $BRTX
    SEC Filings

    View All

    SEC Form 8-K filed by Ensysce Biosciences Inc.

    8-K - Ensysce Biosciences, Inc. (0001716947) (Filer)

    4/3/26 4:14:43 PM ET
    $ENSC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PRE 14A filed by BioRestorative Therapies Inc.

    PRE 14A - BioRestorative Therapies, Inc. (0001505497) (Filer)

    4/3/26 2:46:20 PM ET
    $BRTX
    Managed Health Care
    Health Care

    BioCardia Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - BioCardia, Inc. (0000925741) (Filer)

    4/2/26 9:00:11 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADXS
    $ANPC
    $BCDA
    $BRTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Torti Frank

    4 - Roivant Sciences Ltd. (0001635088) (Issuer)

    4/2/26 7:14:49 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Gline Matthew

    4 - Roivant Sciences Ltd. (0001635088) (Issuer)

    4/1/26 7:20:32 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Sukhatme Mayukh

    4 - Roivant Sciences Ltd. (0001635088) (Issuer)

    4/1/26 7:19:14 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXS
    $ANPC
    $BCDA
    $BRTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bernstein initiated coverage on Roivant Sciences with a new price target

    Bernstein initiated coverage of Roivant Sciences with a rating of Outperform and set a new price target of $35.00

    3/20/26 8:36:50 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on Roivant Sciences with a new price target

    Citigroup initiated coverage of Roivant Sciences with a rating of Buy and set a new price target of $16.00

    9/2/25 8:40:38 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on Genfit with a new price target

    H.C. Wainwright resumed coverage of Genfit with a rating of Buy and set a new price target of $9.00

    8/19/25 8:33:55 AM ET
    $GNFT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADXS
    $ANPC
    $BCDA
    $BRTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Altman Peter bought $5,650 worth of shares (5,000 units at $1.13), increasing direct ownership by 2% to 273,866 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    2/4/26 5:47:41 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Altman Peter bought $1,194 worth of shares (900 units at $1.33), increasing direct ownership by 0.34% to 268,866 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    1/21/26 5:03:15 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Altman Peter bought $1,444 worth of shares (1,100 units at $1.31), increasing direct ownership by 0.41% to 267,966 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    12/17/25 6:32:43 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADXS
    $ANPC
    $BCDA
    $BRTX
    Leadership Updates

    Live Leadership Updates

    View All

    BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality

    SUNNYVALE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces the appointment of Farhan Shahab as Vice President of Quality. Mr. Shahab brings over 25 years of experience to BioCardia in similar executive roles. Mr. Shahab joins BioCardia from Welldoc (a digital health company focused on chronic disease management), where he served as Vice President of Quality and Regulatory. Prior to that, he served as Senior Director of Regulatory Affairs and Quality Assurance at Intuity Medical (a blood glucose monitoring device company), and as Dir

    11/24/25 8:15:00 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio

    MELVILLE, N.Y., Oct. 22, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today announced that Crystal Romano has joined its management team. In her role, Ms. Romano will be responsible for leading BioRestorative's global commercial operations and innovation. A seasoned executive with over 19 years of progressive leadership in the medical, aesthetics, and regenerative industries, Ms. Romano is recognized for her expertise in product development and innovation, commercialization, sales and account management, clinical and product training, a

    10/22/25 9:35:00 AM ET
    $BRTX
    Managed Health Care
    Health Care

    BioSig & Streamex Appoint Defi Expert and Visionary, Russell Starr as Strategic Advisor

    BioSig Technologies, Inc. ("BioSig" or the "Company"), which recently merged with Streamex Exchange Corporation ("Streamex") (NASDAQ:BSGM), is pleased to announce the appointment of Russell Starr as Strategic Advisor to Streamex. Mr. Starr brings decades of experience in capital markets, business development, and transformative deal-making across, defi, traditional finance and emerging sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250711280588/en/ A former executive on Bay Street and respected entrepreneur and financier, Mr. Starr has built a reputation for navigating high-stakes financial transactions and guiding comp

    7/11/25 9:00:00 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ADXS
    $ANPC
    $BCDA
    $BRTX
    Financials

    Live finance-specific insights

    View All

    Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

    Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved therapies exist for LPP, highlighting a critical unmet therapeutic needLPP marks the fourth indication in brepocitinib's expanding late-stage development programMultiple lines of evidence, including strong mechanistic rationale and clinically meaningful results in an investigator-initiated placebo-controlled study of brepocitinib in LPP, support rapid development of brepocitinib in this indicationA seamless Phase 2b/3 potentially registrational trial of brepocitinib in LPP enrolled its

    4/2/26 5:00:00 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioCardia Reports 2025 Business Highlights and Financial Results

    SUNNYVALE, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended December 31, 2025 and filed its annual report on Form 10-K with the Securities and Exchange Commission. The Company will host a corporate update conference call today, on Tuesday, March 24, 2026, at 4:30 PM ET, in which it will discuss business highlights. Call details and dial-in are provided below. Recent Business Highlights CardiAMP® autologous cell therapy in ischemic heart failure of reduced ejection fraction (BCDA-01) In parallel

    3/24/26 4:05:00 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026

    SUNNYVALE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the year ended December 31, 2025 by conference call on Tuesday, March 24, 2026 at 4:30 PM EDT. Following management's formal remarks, there will be a question-and-answer session. Participants can register for the conference by navigating to https://dpregister.com/sreg/10207584/1039b7a7360. Please note that registered participants will receive their dial-in number upon registration. For those who have not

    3/19/26 7:47:51 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADXS
    $ANPC
    $BCDA
    $BRTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Ensysce Biosciences Inc.

    SC 13G - Ensysce Biosciences, Inc. (0001716947) (Subject)

    11/14/24 5:52:56 PM ET
    $ENSC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Roivant Sciences Ltd.

    SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

    11/14/24 4:31:06 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by BioSig Technologies Inc.

    SC 13G/A - BioSig Technologies, Inc. (0001530766) (Subject)

    11/14/24 3:58:00 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care